Skip to main content

Table 1 Characteristics of patients with neuroimmunological disorders and analysis of peripheral blood mononuclear cells.

From: Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders

Neuroimmunological patients α-CD20 control p-values
number of subjects   22 23  
gender female 18 18  
  male 4 5  
age [years] mean (min. - max.) 45 (18-69) 42 (17-69)  
α-CD20 treatment duration [months] mean (min. - max.) 15 (2-47) n.a.  
disorder MS/CIS 8 22  
  NMO 11 1  
  Myasthenia gravis 2 0  
  autoimmune neuropathy 1 0  
CD19 + of all PBMCs [mean % +/- SEM] 0.2 (+/-0.1) 7.9 (+/-1.1) <0.0001
CD4 + of all PBMCs " 37.7 (+/-2.5) 35.9 (+/-1.5) 0.420
CD8 + of all PBMCs " 16.8 (+/-1.8) 15.5 (+/-1.1) 0.768
CD14 + of all PBMCs " 22.3 (+/-2.5) 16.4 (+/-1.4) 0.159
CD4 + of all CD4 + /CD8 + " 69.2 (+/-2.2) 69.8 (+/-1.9) 0.803
CD4 + of all CD4 + /CD8 + /CD14 + " 48.6 (+/-2.9) 53.2 (+/-2.0) 0.271
CD8 + of all CD4 + /CD8 + /CD14 + " 21.3 (+/-2.0) 22.9 (+/-1.5) 0.370
CD14 + of all CD4 + /CD8 + /CD14 + " 30.0 (+/-3.7) 23.9 (+/-2.1) 0.163
CD25 + CD127 - of all CD4 + [median % with 20/80% percentile] 6.8 (5.5-8.4) 5.2 (4.3-6.8) 0.022
  1. Anti-CD20-treated and untreated (control) patients were age- and sex-matched. Frequencies of leucocyte subpopulations are indicated as percentage of all peripheral blood mononuclear cells (PBMCs), and as percentage of CD4+, CD4+/CD8+ or CD14+CD4+/CD8+ PBMCs to "normalize" for treatment-related absence of B-cells. MS = multiple sclerosis; CIS = clinically isolated syndrome; NMO = neuromyelitis optica.